Plenary sessions at AD/PD 2026 featured the most anticipated presentations of the conference, bringing together global leaders in Alzheimer's and Parkinson's research to share transformative findings and vision for the field["@adpd2026"].
Opening Plenary: The Future of Neurodegeneration Research
The opening plenary session set the stage for AD/PD 2026 with presentations on:
Emerging Concepts in Disease Mechanisms
...
Dates: March 17-21, 2026
Location: Copenhagen, Denmark
Organizer: Kenes Group
Overview
Mermaid diagram (expand to render)
Plenary sessions at AD/PD 2026 featured the most anticipated presentations of the conference, bringing together global leaders in Alzheimer's and Parkinson's research to share transformative findings and vision for the field["@adpd2026"].
Opening Plenary: The Future of Neurodegeneration Research
The opening plenary session set the stage for AD/PD 2026 with presentations on:
Emerging Concepts in Disease Mechanisms
Protein Aggregation Kinetics — New understanding of how misfolded proteins propagate between cells
Microglial Phenotypes — Update on disease-associated microglia (DAM) and their role in neurodegeneration
Metabolic Dysfunction — How cellular energy deficits contribute to protein misfolding
Clinical Trial Design Innovations
Biomarker-Driven Enrollment — Using fluid biomarkers for patient selection
Combination Therapy Approaches — Rationale for multi-target interventions
Prevention Trial Designs — Lessons from DIAN-TU and other prevention studies
Alzheimer's Disease Plenary Sessions
Amyloid Hypothesis: Where Do We Stand?
This major plenary reviewed decades of amyloid-targeted therapy development:
Anti-Amyloid Clinical Results
Leqembi (lecanemab) — Real-world effectiveness data and subgroup analyses
Donanemab — TRAILBLAZER-ALZ 2 results and regulatory considerations
Gantenerumab — GRADUATE program outcomes and lessons learned
Future Directions
Amyloid removal versus prevention: different therapeutic windows
Oligomer-targeted approaches: next generation of anti-amyloid therapies
APOE4 carrier considerations in trial design[@crews2023]
Tau Pathology: From Basic Science to Therapy
The tau plenary covered the full spectrum of tau research: